Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ndt/gfm437 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sorafenib as maintenance therapy in FLT3+ acute myeloid leukemia post allogeneic transplantation: a case report.
Anticancer Drugs
February 2025
Pharmacy Service, Hospital Universitario Virgen de las Nieves.
This case report highlights sorafenib as maintenance therapy postallogeneic hematopoietic stem cell transplantation (allo-HSCT) in a young patient with acute myeloid leukemia (AML) with FMS-like tirosine kinase-3 (FLT3)-internal tandem duplication (ITD) mutation. Given the high relapse risk in FLT3-ITD-positive AML, the tyrosine kinase inhibitor sorafenib was administered. Several studies have shown that sorafenib improves survival in younger AML patients when combined with chemotherapy, though side effects can limit use in older patients.
View Article and Find Full Text PDFEfficacy of Ruxolitinib with corticosteroids in idiopathic pneumonia syndrome post-allogeneic hematopoietic stem cell transplantation: A single-center experience and systematic review.
Transpl Immunol
December 2024
Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA. Electronic address:
Article Synopsis
- Idiopathic Pneumonia Syndrome (IPS) is a serious complication that can occur after allogeneic hematopoietic stem cell transplantation (allo-HSCT), potentially leading to high morbidity and mortality, often due to inflammatory damage.
- This study examines the use of Ruxolitinib, a JAK inhibitor, combined with corticosteroids (CS) in treating IPS compared to standard corticosteroid treatment, through a case series of three patients and a systematic review of previous literature involving 346 cases.
- Results indicated that the three patients treated with Ruxolitinib and CS showed significant improvement without mortality linked to IPS, and the systematic review supported these findings across a diverse patient demographic.
Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia.
Blood Cell Ther
August 2024
Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
Early post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) relapse in patients with acute myeloid leukemia (AML) has an almost invariably dismal prognosis. Recent studies have demonstrated that FLT3 inhibition enhances the graft-versus-leukemia effect in vitro and in vivo. Thus, FLT-3 inhibitors may be viable treatment options in this setting.
View Article and Find Full Text PDFSeven-years post allogeneic hematopoietic stem cell transplantation pure red cell aplastic anemia cured with daratumumab: A case report and review of literature.
World J Clin Cases
August 2024
Department of Hematology, The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, Guizhou Province, China.
Background: Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is currently the only viable method of curing patients with acute myeloid leukaemia. In 30% to 50% of patients, donors and recipients have some level of ABO blood group incompatibility. ABO blood group incompatibility can cause antibodies against the donor's red blood cells to persist in the recipient's body, resulting in a delay of several months in the recovery of red blood cells.
View Article and Find Full Text PDFMembranous nephropathy (MN) is one of the most common de novo glomerular diseases developing in patients after allogeneic hematopoietic stem cell transplantation (HSCT). Most authors have used immunosuppression for its treatment to target the underlying immune-mediated processes, akin to graft-versus-host disease, but the optimal management is currently unclear. Limited reports in the literature described the use of a conservative approach with success, particularly in cases with lower risks of progression, such as non-nephrotic-range proteinuria or early reduction of proteinuria by 6 months.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!